Can autoimmune disease be cured by deep CD19+ cell depletion?

Area of Science:

• Immunology
• Autoimmunity
• Cell Biology

Background:

• B cell depletion targeting CD20 has limitations in treating autoimmune diseases, leading to relapses.
• Recent advances prompt a re-evaluation of B cell and plasma cell roles in autoimmunity.

Purpose of the Study:

• To re-evaluate B cell depletion strategies in autoimmunity based on new findings.
• To explore the potential of targeting CD19+ plasma cells for durable autoimmune disease remission.

Main Methods:

• Analysis of clonal CD20- CD19+ plasma cells in anti-CD20 refractory autoimmune disease.
• Review of clinical data on anti-CD19 chimeric antigen receptor T cell therapy efficacy.
• Examination of human CD19+ plasma cell characteristics and function in antigen presentation.

Main Results:

• CD19+ plasma cells are the majority of human plasma cells, are long-lived, and can present autoantigens.
• Autoantigen-binding B cells and CD19+ plasma cells act as key antigen-presenting cells in T cell-mediated autoimmune disorders.
• Anti-CD19 CAR T-cell therapy has shown remarkable clinical remissions in anti-CD20 refractory autoimmunity.

Conclusions:

• Targeting CD19+ plasma cells offers a new strategy for treating autoimmune diseases.
• Deep CD19 depletion may achieve complete and durable remissions in autoantibody-positive autoimmune diseases.